zanubrutinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Mantel Cell Lymphoma

Pending FDA approval for mantle cell lymphoma (MCL)

Next:

Pharmacology

Mechanism of Action

Bruton tyrosine kinase (BTK) inhibitor; BTK is a key component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies

BTK inhibitors block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in certain malignancies

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.